Everything below concerns Pro-Gly-Pro tail. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | ~813.9 Da (free heptapeptide) | N-acetylated form is about 42 Da heavier |
| Residue count | 7 (heptapeptide) | Four residues from ACTH(4-10), three added |
| Appearance | White to off-white powder | Usually supplied lyophilized |
| Solubility class | Freely soluble in water | Also dissolves in DMSO and polar organic solvents |
| Related parent fragment | ACTH(4-10) | Parent motif is Met-Glu-His-Phe |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
The latter may be involved in the effectiveness of propranolol in the treatment of migraine at high doses. (–)-Propranolol is not a silent antagonist of the serotonin 5-HT1A receptor but is instead a very weak partial agonist of the receptor. Both enantiomers of propranolol have a local anesthetic (topical) effect, which is normally mediated by blockade of voltage-gated sodium channels. Studies have demonstrated propranolol's ability to block cardiac, neuronal, and skeletal voltage-gated sodium channels, accounting for its known membrane stabilizing effect and antiarrhythmic and other central nervous system effects.
== Preparation == DraxImage MAA kits for preparing 99mTc-MAA are available in the United States from only a single manufacturer; Jubilant DraxImage Inc. The kits are delivered to nuclear pharmacies as lyophilized powders of non-radioactive ingredients sealed under nitrogen. A nuclear pharmacist adds anywhere from 50 - 100 mCi of Na[99mTcO4] to the reaction vial to make the final product, in the pH range of 3.8 to 8.0. After being allowed to react at room temperature for 15 minutes to ensure maximum labeling of the human albumin with 99mTc, the kit can then be diluted with sterile normal saline as needed. Once prepared the product will have a turbid white appearance.
SO2 + HO• → HSO3 HSO3 + O2 → SO3 + HO2 SO3 + H2O → H2SO4 Because sulfuric acid reaches supersaturation in the stratosphere, it can nucleate aerosol particles and provide a surface for aerosol growth via condensation and coagulation with other water-sulfuric acid aerosols. This results in the stratospheric aerosol layer.
== Births == 13 December - Robert Griffiths, inventor (died 1883) 19 December - John David Edwards, hymn-writer (died 1885) date unknown Evan Davies, missionary (died 1864) Hugh Hughes (Tegai), writer (died 1864) John William Thomas, mathematician (died 1840)
stop codon Also termination codon. A codon that signals the termination of protein synthesis during translation of a messenger RNA transcript. In the standard genetic code, three different stop codons are used to dissociate ribosomes from the growing amino acid chain, thereby ending translation: UAG (nicknamed "amber"), UAA ("ochre"), and UGA ("opal"). Contrast start codon.
Sources: en.wikipedia.org
=== Chirality and mirror symmetry === A nanotube is chiral if it has type (n,m), with m > 0 and m ≠ n; then its enantiomer (mirror image) has type (m,n), which is different from (n,m). This operation corresponds to mirroring the unrolled strip about the line L through A1 that makes an angle of 30 degrees clockwise from the direction of the u vector (that is, with the direction of the vector u+v). The only types of nanotubes that are achiral are the (k,0) "zigzag" tubes and the (k,k) "armchair" tubes. If two enantiomers are to be considered the same structure, then one may consider only types (n,m) with 0 ≤ m ≤ n and n > 0. Then the angle α between u and w, which may range from 0 to 30 degrees (inclusive both), is called the "chiral angle" of the nanotube.
Concurrently, a line of work led by Mary Higby Schweitzer, Jack Horner, and colleagues reported various occurrences of preserved soft tissues and proteins within dinosaur bone fossils. Various mineralized structures that likely represented red blood cells and collagen fibres had been found by Schweitzer and others in tyrannosaurid bones as early as 1991. However, in 2005, Schweitzer and colleagues reported that a femur of Tyrannosaurus preserved soft, flexible tissue within, including blood vessels, bone matrix, and connective tissue (bone fibers) that had retained their microscopic structure. This discovery suggested that original soft tissues could be preserved over geological time, with multiple mechanisms having been proposed. Later, in 2009, Schweitzer and colleagues reported that a Brachylophosaurus femur preserved similar microstructures, and immunohistochemical techniques (based on antibody binding) demonstrated the presence of proteins such as collagen, elastin, and laminin. Both specimens yielded collagen protein sequences that were viable for molecular phylogenetic analyses, which grouped them with birds as would be expected. The extraction of fragmentary DNA has also been reported for both of these fossils, along with a specimen of Hypacrosaurus. In 2015, Sergio Bertazzo and colleagues reported the preservation of collagen fibres and red blood cells in eight Cretaceous dinosaur specimens that did not show any signs of exceptional preservation, indicating that soft tissue may be preserved more commonly than previously thought.
Orbitrap analyzers are similar to FTMS analyzers. Ions are electrostatically trapped in an orbit around a central, spindle shaped electrode. The electrode confines the ions so that they both orbit around the central electrode and oscillate back and forth along the central electrode's long axis. This oscillation generates an image current in the detector plates which is recorded by the instrument. The frequencies of these image currents depend on the mass-to-charge ratios of the ions. Mass spectra are obtained by Fourier transformation of the recorded image currents. Orbitraps have a high mass accuracy, high sensitivity and a good dynamic range. They are also quite small.
In Lebanese nationalist narratives, Fakhr-al-Din II is celebrated as establishing a sort of Druzes–Maronite condominium that is often portrayed as the embryo of Lebanese statehood and national identity. Nationalist narratives by Lebanese Druze and Maronites agree on Fakhr al-Din's "decisive influence and contribution to Lebanon's history", according to the historian Yusri Hazran, though they differ significantly in determining the Emir's motives and the historic significance of his rule. Druze authors describe him as the ideal ruler who strove to achieve strong domestic unity, build a prosperous economy, and politically free Lebanon from Ottoman oppression. Making the case that the Ma'nids worked toward Lebanon's integration into the Arab regional environment, the Druze authors generally de-emphasize his relations with Europe and portray his drive for autonomy as the first forerunning of the Arab nationalist movement. On the other hand, Maronite authors viewed the legacy of Fakhr al-Din as one of isolation from the Arab–Islamic milieu. Fakhr al-Din himself has been adopted by a number of Maronite nationalists as a member of the religious group, citing the refuge he may have taken with the Khazens in Keserwan during his adolescence, or claiming that he had embraced Christianity at his deathbed. According to the historian Christopher Stone, Fakhr al-Din was used by the Rahbani brothers in their Lebanese nationalist play, The Days of Fakhr al-Din, as "a perfect historical predecessor for Lebanon's Christian nationalism of the twentieth century".
Sources: en.wikipedia.org
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.
Semax is a synthetic analog of the ACTH(4-10) fragment rather than a copy of the full hormone. Truncation plus the added tail removes the steroidogenic portion of ACTH. That distinction explains why it is studied for nervous-system effects instead of adrenal stimulation.
It is registered as a prescription product in Russia and has been used there clinically, chiefly by the intranasal route. No approval exists in the United States or the European Union. Availability elsewhere typically falls under research-chemical distribution, with varying purity documentation.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.